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Abstract
Background: There are limited data on the prognosis of deferral of lesion treatment in patients with acute coronary 
syndrome (ACS) based on fractional flow reserve (FFR).
Objectives: To provide a systematic review of the current evidence on the prognosis of deferred lesions in ACS patients 
compared with deferred lesions in non-ACS patients, on the basis of FFR.
Methods: We searched Medline, EMBASE, and the Cochrane Library for studies published between January 2000 and 
September 2017 that compared prognosis of deferred revascularization of lesions on the basis of FFR in ACS patients 
compared with non-ACS patients. We conducted a pooled relative risk meta-analysis of four primary outcomes: mortality, 
cardiovascular (CV) mortality, myocardial infarction (MI) and target-vessel revascularization (TVR).
Results: We identified 7 studies that included a total of 5,107 patients. A pooled meta-analysis showed no significant 
difference in mortality (relative risk [RR] = 1.44; 95% CI, 0.9–2.4), CV mortality (RR = 1.29; 95% CI = 0.4–4.3) and TVR 
(RR = 1.46; 95% CI = 0.9–2.3) after deferral of revascularization based on FFR between ACS and non-ACS patients. 
Such deferral was associated with significant additional risk of MI (RR = 1.83; 95% CI = 1.4–2.4) in ACS patients.
Conclusion: The prognostic value of FFR in ACS setting is not as good as in stable patients. The results demonstrate an 
increased risk of MI but not of mortality, CV mortality, and TVR in ACS patients. (Arq Bras Cardiol. 2018; [online].ahead 
print, PP.0-0)
Keywords: Acute Coronary Syndrome/physiopathology; Percutaneous Coronary Intervention/methods; Coronary Angiography/
methods; Fractional Flow Reserve Myocardial/physiology; Microvessels; Vascular Resistance; Reproducibility of Results.
Introduction
Fractional flow reserve is a well-validated, effective technique 
to determine the functional significance of intermediate coronary 
lesions; FFR-guided percutaneous coronary intervention (PCI) 
improves clinical outcomes in patients with stable coronary 
disease.1-3 Although robust data supports FFR use in stable 
coronary disease, its use in acute coronary syndrome (ACS) is 
less well investigated because maximal hyperemia is required 
to accurately measure FFR. In patients with ACS, microvascular 
changes may prevent vasodilatation thus affecting the validity of 
FFR.1,4-6 These changes appear to be vessel-dependent (culprit vs. 
non-culprit) and related to the type of infarction – ST-elevation 
myocardial infarction (STEMI) vs. non-ST-elevation myocardial 
infarction (NSTEMI).7 FFR values in the culprit vessel are 
recognized to be higher when measured during acute episodes 
than when measured after the microcirculation has had some 
time to recover. Higher FFR values are assumed to be caused 
by reduced levels of hyperemia in the culprit vessel due to 
embolization of thrombus and plaque, ischemic microvascular 
dysfunction and myocardial stunning. Hence, efficacy of the use 
of FFR in culprit artery disease remains uncertain.8,9
Multivessel coronary disease (MVD), observed in 
approximately 30-50% of patients presenting with STEMI 
and in 30-59% with NSTEMI, is associated with a poor 
prognosis.10-12 Complete revascularization of hemodynamically 
significant vessels identified in the hemodynamic laboratory 
early after acute event appears attractive: this approach 
provides the patient with a well-defined, definitive therapeutic 
plan. However, several studies suggest that a FFR-guided 
revascularization strategy in ACS reduces the rate of coronary 
revascularization without compromising short-term safety.13-15 
However, the results of this approach are inconsistent in 
several studies involving patients with non-ACS.13,14
Therefore, the aims of this study are to provide a systematic 
review of the current evidence of the deferral of PCI based 
on FFR in ACS patients and compare it with that supporting 
this decision in non-ACS patients.
Methods
Data sources and searches
We systematically searched MEDLINE, EMBASE, and the 
Cochrane Library for relevant articles published between 
Original Article
Martins
ACS Fractional flow reserve-guided strategy
Arq Bras Cardiol. 2018; [online].ahead print, PP.0-0
January 2000 and September 2017. Previous qualitative 
and systematic reviews, if available, were searched for 
additional studies. The query terms “Flow Fractional Reserve” 
OR “Acute Coronary Syndrome” were used in the search. 
References of the studies identified by the search strategy 
were reviewed for potentially relevant articles not identified 
by the above search. No language restrictions were enforced.
Study selection
The title/abstract of citations were first screened by 2 
independent reviewers (JM and VA), and complete manuscripts 
were retrieved if considered potentially relevant. Additional studies 
were identified by reviewing the bibliographies of included studies 
and relevant reviews. Disagreements were resolved by consensus. 
The same reviewers independently appraised identified articles 
according to the following inclusion criteria: studies that compared 
clinical outcomes of lesions after PCI deferred based on FFR 
between ACS patients and non-ACS patients (Figure 1).
Endpoints
The endpoints studied were: mortality, cardiovascular 
mortality, myocardial infarction (MI), and target vessel 
revascularization (TVR) during the follow-up period. TVR of the 
target vessel was defined as subsequent revascularization of the 
index vessel by either PCI or bypass grafting. In all trials, in the 
ACS group, distinction between culprit and non-culprit lesions 
was based on the operator’s discretion, and hence subjective, 
similar to clinical practice.
Statistical analysis
Continuous variables were expressed as means ± 
standard deviations or median (with interquartile range) 
values, and categorical variables were described as 
numbers and percentages. To calculate pooled effect 
estimates, we used the inverse variance assuming a 
fixed-effects model and the DerSimonian-Laird method 
assuming a random-effects model.16 Homogeneity among 
the studies was evaluated using Cochran’s Q test and the 
I2 statistic (the values of 0.25, 0.50, and 0.75 indicated 
low, moderate, and high degrees of heterogeneity, 
respectively). Publication bias was evaluated using funnel 
plots. We performed a sensitivity analysis to evaluate the 
impact of each study on the results. MetaXL 2.0 (EpiGear 
International Pty Ltd, Wilston, Queensland, Australia) was 
used to calculate the pooled risk difference effect sizes 
(difference in occurrence risk between revascularization 
and conservative management groups).
Results
Study identification
The search strategy initially retrieved 129 citations. Of 
these, 96 articles were excluded after review of the title or 
abstract. After assessment or the studies for the selection 
criteria, we excluded an additional 26 studies. A total of 7 
studies met criteria for the meta-analysis, involving 5,107 
(3,540 non-ACS and 1,567 ACS) patients.
Figure 1 – Flowchart of studies included in the meta-analysis.
928 articles searched (published
between January 1, 2000 and
September, 2017)
Duplicate studies removed (n = 3)
129 articles screened
33 full text articles screened
7 articles included
Exclusion by title and
abstract screening (n = 96)
Exclusion by full
text screening (n = 26)
Exclusion criteria:
• Study design
– review (n = 20)
– editorial (n = 3)
– no discrimination in outcomes
between ACS vs non-ACS (n = 3)
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Characteristics of included studies
Of the 7 studies included, 1 was a prospective study and 6 had 
an observational, retrospective in design (Table 1 and Table 2).
Quantitative synthesis of outcomes
Mortality: We included 3 studies, a total of 2,074 patients, 
in the pooled analysis. The forest plot (Figure 2) describes 
the weighted meta-analysis for relative risk (RR) of mortality 
in ACS patients in comparison with non-ACS patients when 
revascularization decisions were based on FFR. Pooled analysis 
showed negligible heterogeneity among the studies (I2 = 0%; 
p = 0.78) and the ACS and non-ACS patients did not differ 
significantly; their pooled RR was 1.44 (95% CI = 0.89–2.35). 
Exclusion of any single study did not significantly alter the 
overall combined result.
Cardiovascular mortality: We included 5 studies, a total of 
3,144 patients, in the pooled analysis. The forest plot (Figure 2) 
describes the weighted meta-analysis for mortality risk of basing 
revascularization decisions on FFR. Pooled analysis showed 
significant heterogeneity among the studies (I2 = 70%; 
p = 0.01) and the ACS and non-ACS patients did not differ 
significantly; their pooled RR was 1.29 (95% CI = 0.39–4.25). 
Exclusion of any single study did not significantly alter the 
overall combined result.
Myocardial Infarction: 7 studies were included, a total 
of 5,107 patients, in the pooled analysis. Deferring lesions 
based on FFR was associated with a significant additional 
risk of MI (RR = 1.83; 95% CI = 1.39–2.40) in ACS patients 
versus non-ACS patients. Figure 2 describes the weighted 
meta-analysis of MI. The pooled analysis showed negligible 
heterogeneity among the studies (I2 = 0%; p = 0.96).
Target-vessel revascularization: We included 5 studies, a total 
of 3,475 patients, in the pooled analysis. The forest plot (Figure 2) 
describes the weighted meta-analysis of TVR in patients when 
revascularization decisions were based on FFR. Pooled analysis 
showed negligible heterogeneity among the studies (I2 = 39%; 
p = 0.16). ACS and non-ACS patients did not differ significantly 
in RR of TVR; their pooled RR was 1.46 (95% CI = 0.93–2.29).
Study Bias
Visual inspection of the funnel plots for the outcomes did 
not reveal any asymmetry among the studies. Further, the Begg 
rank correlation test was not statistically significant.
Discussion
This report provides a systematic review and a meta-analysis 
comparing the strategy in patients in whom lesion treatment 
was deferred based on FFR, and no revascularization was 
undertaken in ACS patients to that in non-ACS patients. 
FFR-guided revascularization in ACS patients appears to be 
as safe as in non-ACS patients.2,17-18 Briasoulis et al.,15 in a 
meta-analysis, evaluated FFR-guided management in NSTEMI 
patients, where a modest reduction in incidence of MI was 
noted, with no significant differences in incidence of major 
adverse cardiac events (MACE), death or all-cause mortality, and 
target-vessel revascularization between the FFR guided approach 
in comparison with coronary angiography-guided approach.15
Four important pathophysiological considerations need to 
be considered when comparing the FFR results in ACS patients 
to those of non-ACS patients:
1. Microvascular dysfunction: The timing of FFR 
measurement in the ACS patient is an important 
issue. As described above, immediately after MI, the 
initial, temporary microvascular injury caused by the 
inflammatory environment may artificially elevate the 
initial FFR measurements. Antithrombotic therapy, 
administered for 3 to 4 days to stabilize the plaque, may 
reduce microvascular dysfunction, and FFR may then 
reflect the true hemodynamic situation. This approach 
of waiting > 5 days to measure FFR in ACS patients 
was suggested by the European Society of Cardiology 
guidelines.19-21 However, most referral centers that study 
FFR in ACS perform early invasive evaluation of ACS 
patients, within 48 h of presentation, a practice that could 
lead to artificially higher FFR values.19,22-27,34,37,38
2. Plaque instability: At least two-thirds of lesions arising 
from vessels with < 50% stenosis are responsible 
for unstable syndromes involving plaque instability, 
assuming that these vessels previously had normal flow. 
A non-flow-limiting culprit lesion may be "anatomically 
significant" but "physiologically nonsignificant", and 
because FFR is not intended to evaluate plaque 
characteristics, care must be taken in the use of FFR in 
vessels with unstable characteristics but normal flow.28,29
3. Myocardial mass involved: The mass of viable 
myocardium being perfused by the artery in question 
is relevant pathophysiologically to the interpretation of 
FFR results in ACS patients. The FFR value is inversely 
proportional to the ejection fraction: hence, a lower 
ejection fraction, which implies a large area of infarction 
with less viable myocardium, could produce a higher 
FFR reading for the same degree of stenosis.14,30
4. Presentation type of ACS: Because ACS describe 
a range of myocardial ischemic states with distinct 
clinical and pathophysiological characteristics, the 
use of FFR should be differentiated by type of ACS. 
DANAMI3-PRIMULTI and COMPARE ACUTE were the 
only studies that evaluated the risk of events following 
FFR-guided PCI in patients with STEMI and MVD.31,32 
Of these, only COMPARE ACUTE reported the rate of 
events at follow-up in patients whose PCI was deferred 
based on FFR; patients who did not undergo additional 
revascularization had a similar event rate to those who 
were revascularized based on positive (elevated) FFR. 
On the other hand, FAME, which included 328 patients 
with ACS out of a total of 1,005 patients with MVD, 
reported similar rates of mortality, MI, or revascularization 
in non-ST-segment elevation acute coronary syndrome 
(NSTE-ACS) patients who had PCI deferred based on an 
FFR cutoff value > 0.80 compared to non-ACS patients.24 
However, the FAME study did not define the exact time 
of FFR measurement nor the lesions assessed (culprit vs. 
non-culprit). Furthermore, the event rate in patients with 
deferred PCI based on FFR was not reported. In addition, 
the FAMOUS-NSTEMI trial compared a FFR-guided 
versus an angiography-only approach in NSTEMI and 
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Table 1 – Characteristics of included studies
Author
Year
Follow up
Study design
Total FU
Age (yrs)
Men
Non-ACS 
(n)
ACS 
(n)
STEMI 
(n)
NSTEMI/
UA (n)
FFR value 
used to defer
Median tim
e 
between Clinical 
presentation and FFR 
m
easurem
ent
Multivessel 
disease
Adenosine adm
inistration
Exclusion criteria
Potvin JM 
et al 9
2006
11 ± 6 months
Retrospective 
cohort
201
62 ± 10
131
61
124
11
113
≥ 0.75
24 hours (range 
2 to 144)
NR
intracoronary administration 
of adenosine (median dose 
60 μg, range 30 to 300, for 
the left coronary artery and 
30 μg, range 18 to 120, for 
the right coronary artery) and/
or nitroprusside (median dose 
250 μg, range 100 to 1,000, 
for the left and right coronary 
arteries). Intracoronary 
adenosine was used in 
135 cases, intracoronary 
nitroprusside in 14 cases, and 
adenosine and
nitroprusside in 52 cases
Patients within 24 hours 
of acute STEM
I 
were excluded
Fischer J 
et al 8
2006
12 months
Retrospective 
cohort
111
ACS →
 58 ± 14
Non-ACS →
 
63 ± 10
72
76
35
11
24
≥ 0.75
Recent
(within 7 days) ST 
segment elevation 
M
I treated with 
lytic Therapy
ACS →
 9
Non-ACS 
→
 9
intracoronary adenosine (30 μg 
bolus in the right coronary 
artery or 40–60 μg bolus in the 
left coronary artery
NR
Sels et 
al 24
2011
2 years
Prospective 
cohort
1005
ACS →
 
64.8 ± 10.7
Non-ACS →
 
64.3 ± 10
744
677
328
0
328
≥ 0.80
NR
NR
Intravenous adenosine, 
administered at a rate of 
140 μg/kg/m
in through a 
central vein.
Exclusion criteria were 
left m
ain disease, 
previous CABG
, and 
STEM
I < 5 days before, 
because the use of 
FFR is not validated in 
recent STEM
I. Patients 
admitted for UA and 
NSTEM
I with positive 
troponin but total creatine 
kinase < 1,000 U/l could 
be included
Mehta 
et al 25
2015
3.4 ± 1.6 years
Retrospective 
cohort
674
ACS →
 
63.8 ± 11.9
Non-ACS →
 
65.3 ± 10.2
380
340
334
7
327
> 0.80
NR
ACS →
 221
Non-ACS 
→
 209
Predominant use of 
intracoronary adenosine with 
similar maximum doses for 
both groups (120 μg)
NR
Hakeem
 A 
et al 34
2016
3,4 ± 1,6 anos
Retrospective 
cohort
576
ACS →
 66.6 ± 8
Non-ACS →
 
64.7 ± 8.7
554
370
206
0
206
> 0.75
NR
ACS →
 135
Non-ACS 
→
 216
Intravenous (140 m
g/kg/m
in)  
or intracoronary (at 
least 60 m
g) adenosine. 
The median dose of 
intracoronary  adenosine in 
our cohort was 130 mg
NR
Van Belle 
et al 38
2017
1 year
Retrospective 
cohort
958
ACS →
 66 ± 11.2
Non-ACS →
 
66.4 ± 10
693
721
237
-
-
> 0.75 e > 0.80
NR
NR
NR
NR
Lee JM 
et al 37
2017
722 days
Retrospective 
cohort
1596
ACS →
 62.0 
± 11.1
Non-ACS →
 
62.4 ± 9.4
1112
1295
301
0
301
> 0.80
NR
NR
Hyperemia was induced 
with an intracoronary bolus 
adm
inistration (80 μg in 
left coronary artery, 40 μg 
in right coronary artery), 
intracoronary  (240 μg/
m
in) or, iv continuous 
infusion (140 μg/Kg/m
in) 
of adenosine.
NR
FU: Follow-up; yrs: years; ACS: acute coronary syndrom
e; STEM
I: ST segm
ent elevation m
yocardial infarction; NSTEM
I: non- ST segm
ent elevation m
yocardial infarction; UA: unstable angina; FFR: fractional flow reserve; PCI: Percutaneous coronary intervention; M
I: M
yocardial Infarction; TVR: target vessel 
revascularization; CABG: Coronary artery bypass grafting; NR: not reported.
Original Article
Martins
ACS Fractional flow reserve-guided strategy
Arq Bras Cardiol. 2018; [online].ahead print, PP.0-0
Table 2 – Clinical outcomes of ACS and non-ACS patients with deferred lesion treatment based on fractional flow reserve
Author Year Patients[FFR > cutoff] * Mortality CV Mortality
Myocardial 
infarction
Target lesion 
revascularization
Target vessel 
revascularization
Potvin JM 
et al 9 2006
ACS → 124
Non-ACS → 61 NR
ACS → 0
Non-ACS → 1
ACS → 2
Non-ACS → 1 NR
ACS → 11
Non-ACS → 7
Fischer J. 
et al 8 2006
ACS → 35
Non-ACS → 76
ACS → 3
Non-ACS → 5
ACS → 2
Non-ACS → 1
ACS → 1
Non-ACS → 1 NR
ACS → 6
Non-ACS → 7
Sels et al 24 2011 NR** ACS → 12Non-ACS → 20 NR
Non-ACS → 36
Non-ACS → 44 NR
ACS → 45
Non-ACS → 72
Mehta 
et al 25 2015
ACS → 334
Non-ACS → 340 NR
ACS → 23 
Non-ACS → 8
ACS → 47
Non-ACS → 26
ACS → 78
Non-ACS → 66 NR
Hakeem A 
et al 34 2016
ACS → 206
Non-ACS → 370 NR
ACS → 9
Non-ACS → 30
ACS → 16
Non-ACS → 11
ACS → 36
Non-ACS → 29
ACS → 15 
Non-ACS → 14
Van Belle 
et al 38 2017
ACS → 237
Non-ACS → 721
ACS → 10
Non-ACS → 17 NR
ACS → 3
Non-ACS → 7 NR
NR
***ACS → 9;
***Non-ACS → 42]
Lee JM 
et al 37 2017
ACS → 301
Non-ACS 1295 NR
ACS → 3
Non-ACS → 5
ACS → 2
Non-ACS → 4
ACS → 8
Non-ACS → 10
ACS: acute coronary syndrome; CV: cardiovascular; NR: not reported; *Cut-off values varied from 0.75 to 0.80 among the studies; ** Sels et al.24 evaluated whether 
there is a difference in benefit of fractional flow reserve (FFR) guidance for percutaneous coronary intervention (PCI) in multivessel coronary disease in patients with 
acute coronary syndrome (ACS) vs. non-ACS without discriminating those patients with FFR > 0.80; *** Target-vessel revascularization was not specified.
MVD patients; the rate of major adverse cardiac events 
(defined as cardiac mortality or hospitalization for MI 
or heart failure) was 7.5% in patients with deferred 
PCI based on FFR and 0% in those deferred PCI 
based on angiography.13
The aim of this analysis was not to evaluate FFR-guided 
decisions per-lesion level, but rather to focus on the relevance 
of FFR-guided decision per-patient level, considering that 
patients with ACS frequently have more than 1 lesion suitable 
for revascularization and the identification of the culprit 
lesion is not always straightforward. Undoubtedly, patients 
with MVD have worse outcomes than patients who present 
with single vessel disease. The natural history of patients 
who are revascularized in an acute setting is known to differ 
from those who are revascularized in a stable setting.33 
For example, the probability of malignant dysrhythmias 
is significantly more common in acute patients and is an 
important cause of mortality.33
This systematic review and meta-analysis summarizes 
all published studies that assessed and compared clinical 
outcomes in which revascularization decisions were based 
on FFR in ACS versus non-ACS setting. Among the clinical 
endpoints evaluated, only the RR of MI was significantly higher 
in patients with ACS.
The higher risk of subsequent MI found in this study and by 
several authors is explained by the different pathophysiology 
of ACS versus stable coronary disease.34-36 Hakeem et al. 
compared the outcomes in NSTEMI patients who did not 
undergo PCI of any lesion on the basis of FFR to those in a 
similar group of non-ACS patients. After an average 3.4-years 
follow-up, using propensity score matching, the MI and TVR 
rates were higher in NSTEMI patients than in non-ACS patients 
(25% vs. 12%, respectively; p < 0.0001).34 Similar results were 
reported recently by Lee et al. in non-ACS patients.37
When MI injury (defined as any MI attributable to a 
deferred revascularization based on the index FFR) was 
specifically evaluated, deferring treatment of lesions based on 
FFR did not differ significantly in the RR of MI injury between 
ACS and non-ACS patients [RR 1.84 (95% CI = 0.82–4.11); 
(I2 = 0%; p = 0.98)] (Figure 3).
If on the one hand, Briasoulis et al.15 showed that a 
FFR-guided strategy in ACS seems to be associated with a 
better prognosis compared to an angiography strategy, the 
primary finding of our study was that deferring the treatment 
of lesions was associated with an increased risk of MI in ACS 
patients compared to non-ACS patients, represented by 
the RRs of the target-vessel revascularization or MI lesion.15 
In addition, mortality and CV mortality did not differ between 
ACS and non-ACS patients.
Our results are consistent with the recently published 
study by Van Belle et al.,38,39 who compared the impact 
differing the management of intermediate lesions, based 
on FFR, on the prognosis of ACS vs. non-ACS patients from 
two important registries, R3F and POST-iT. They concluded 
that revascularization decisions based on FFR for differing 
treatment of lesions were safe in ACS patients.38-40
 Some authors have questioned whether we should be 
less permissive and adopt a different cut-off value for FFR in 
unstable vessels. Hakeem et al.,34 recently determined that the 
best FFR cut-off value for predicting MI or TVR was > 0.80 
in patients with stable coronary artery disease, supporting 
current practice. However, in NSTE-ACS patients, the best 
cutoff value was >0.84. However, some limitations suggested 
by some authors deserve consideration in interpreting their 
results. For example, it is unclear why mortality, the most 
important outcome, was not included in the composite 
endpoint in this study. In addition, medical therapy was not 
optimal for the patients, 14% of patients did not receive statin, 
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Figure 2 – Forest plots of the pooled risk ratio of the outcomes. (A) mortality, (B) cardiovascular mortality; (C) myocardial infarction; (D) target-vessel revascularization. 
Size of data markers reflects the relative weight of the study. CI indicates confidence interval.
Study
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and approximately two-thirds did not receive dual antiplatelet 
therapy. Moreover, several technical issues might explain the 
higher FFR cut-off values reported in these studies.34,41-43
Despite most of the studies included did not report clinical 
outcomes by type of lesions (culprit or non-culprit) lesions, 
available evidence suggests, as previously mentioned, that 
in patients with ACS, microvascular dysfunction may be less 
marked, and the ability to achieve maximal hyperemia is 
sufficient to maintain the diagnostic use of FFR, both in culprit 
and non-culprit vessels.44
Figure 3 – Forest plot of the pooled risk ratio for myocardial infarction injury. Size of data markers reflects the relative weight of the study. CI indicates confidence interval.
Study
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